At @-year follow-up , patients in the trimetazidine group ( n = @ ) showed significant improvements in the incidence ( P = @ ) and severity of angina pectoris , compared with the control group , as well as silent myocardial ischaemia ( P = @ ) and angina pectoris-free survival ( P = @ ) .